Sign up
ZYME

Zymeworks Inc. Common Stock (NASDAQ: ZYME)

Healthcare · Biotechnology

$26.04+0.20 (+0.77%)

Last close · Nov 18, 2026 · NASDAQ USD

Set alert

The Quantellect read. ZYME rose 0.77% in the Nov 18 session to $26.04, which is 17.2% below its 52-week high of $31.46. Short interest is 8.99% of float with a 0.41% borrow fee. 11 active firms cover the stock as of Nov 19, 2026; ten active firms with targets average $43.00 over 12 months, and the next earnings report is due Mar 4, 2027. Descriptive summary of the data on this page, not a recommendation.

Relative valuationHigher multiples than peers

P/S 55.4× vs peer median 13.9×

MomentumNeutral

RSI (14) 42.7 (overbought above 70, oversold below 30)

Trend—

—

Short interest9.0% of float

FINRA settlement Oct 30, 2026

ZYME price chart

Price $26.04 · As of Nov 18, 2026, 3:59 PM ET

Open full chart →
Price details unavailable for this range.

Chart loads when this section enters view.

Text price and event history
6M plotted price range (ET)
Range6M
First date—
Last date—
Open—
High—
Low—
Close—
Volume—
Plotted bars0

Plotted OHLCV bars

No price bars are available for this range.

Event records

Event records load after the price chart.

Split-adjusted daily prices · Price as of —

Initial 6M price range summary
Range6M
First close—
Last close—
High—
Low—
Volume—
Open
$25.65Nov 18, 2026 session
Previous close
$25.84Nov 17, 2026 close
Day range
$24.88 – $26.24Nov 18, 2026 session
52-week range
$21.81 – $31.46Through Nov 18, 2026
Volume
1.02MNov 18, 2026 session
Average volume (30 calendar days, 0 sessions)
—Through Nov 18, 2026
Market cap$2.06B
P/E (TTM)3.8
Forward P/E31.3
EPS (TTM)stale vendor snapshot —
Dividend yielddata unavailable —
Beta (5-year monthly vs SPY)1.31

Price history

ZYME · NASDAQ · USD

Split-adjusted · volume in shares

Price history unavailable

Notable price movement

— · Notable price movement not available

Options flow

— · Options flow not available

Q Score

— · Q Score not available

Quantellect signals

Change since Nov 17
Squeeze28Idle—
How the scores work →

How ZYME compares with its industry

Against 592 other US-listed Biotechnology stocks

Dot = rank among peers, low to high · tick = peer median · colour marks the top and bottom 10%

Strongest points

  1. Three-month return was -5%, higher than 84% of 559 peers.Peer median −31.7% · As of Nov 16, 2026

Points of caution

  1. Latest-quarter year-over-year sales growth was -90.6%, with only 12% of 592 peers reporting a lower value.Peer median 0.0% · As of Nov 17, 2026
  2. Trailing-year net margin was 0%, with only 19% of 583 peers reporting a lower value.Peer median 0.0% · As of Nov 17, 2026

Valuation

Higher multiples than peers

  • Price/sales55.41×13.85×

    Higher than 72% of 407 peers

  • Forward P/E21.69×14.84×

    Not ranked: only 193 of 592 peers report it

  • Price/book25.60×2.57×
    Highest 10%

    Higher than 92% of 551 peers

Profitability

Profitability metrics are lower than most peers.

  • Gross margin—78.4%

    Not ranked: only 247 of 592 peers report it

  • Operating margin—0.0%

    Not ranked: only 443 of 592 peers report it

  • Net margin0.0%0.0%

    Higher than 19% of 583 peers

  • Return on equity−72.3%−67.8%

    Higher than 48% of 554 peers

Growth

Growth metrics are lower than most peers.

  • Quarterly sales growth, year over year−90.6%0.0%

    Higher than 12% of 592 peers

  • 5-year sales growth rate22.2%11.0%

    Not ranked: only 139 of 592 peers report it

Balance sheet

Balance sheet metrics are lower than most peers.

  • Current ratio3.305.03

    Higher than 35% of 498 peers

  • Debt/equity (total borrowings)1.310.23

    Not ranked: only 116 of 592 peers report it

Momentum

Returns are higher than most peers.

  • 1-year return+39.5%−29.8%

    Higher than 82% of 522 peers

  • 6-month return+5.9%−24.0%

    Higher than 73% of 547 peers

  • 3-month return−5.0%−31.7%

    Higher than 84% of 559 peers

Compared with 592 other US-listed Biotechnology stocks · fundamentals as of Nov 1, 2026 · prices as of Nov 12, 2026

Upcoming events

  • ZYME earnings report

    Consensus EPS estimate $0.08.

Analyst consensus

Buy

0Strong Buy
11Buy
0Neutral
0Sell
0Strong Sell

Based on 11 active firms as of Nov 19, 2026 (365-day activity window)

12-month price targets (third-party analysts)

Low$32.00
Average$43.00
High$58.00

As of Nov 19, 2026 across 10 active firms with targets. Targets are published by third-party analysts, not by Quantellect.

Full analyst forecast →

Earnings history

EPS, last 8 quarters
EstimateBeatMissMatch
Fiscal periodEst.ActualResult
Q3 2026$2.19$2.28—
Q2 2026—−$0.62—
Q1 2026—−$0.59—
Annual 2025−$0.32−$1.08—
Q3 2025−$0.32−$0.26—
Q2 2025−$0.52$0.03—
Q1 2025−$0.70−$0.30—
Annual 2024−$0.09−$1.62—

Next: Mar 4, 2027, estimate $0.08

Smart-money activity

In the last 60 days: 0 insider sales and 0 purchases. Last quarter: 0 new 13F positions. No congressional trades in 90 days.

DateTypeWhoActionAmountSource
13FPoint72 Asset Management, L.P.Closed position$013F filing
13FCITADEL ADVISORS LLCClosed position$013F filing
13FMILLENNIUM MANAGEMENT LLCClosed position$013F filing
13FD. E. Shaw & Co., Inc.Closed position$013F filing
13FRENAISSANCE TECHNOLOGIES LLCClosed position$013F filing
Insider sellJosephson NeilSell$20.0KForm 4
13FPoint72 Asset Management, L.P.Opened position$1.5K13F filing
13FCITADEL ADVISORS LLCReduced position$75813F filing
13FMILLENNIUM MANAGEMENT LLCOpened position$1.2K13F filing
13FRENAISSANCE TECHNOLOGIES LLCOpened position$35513F filing
All smart-money activity →

News and press releases

All ZYME news →

Company profile

Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a

CEO
Mr. Kenneth H. Galbraith C.A.
Headquarters
Middletown, DE, United States
Employees
231
IPO date
Apr 28, 2017
Sector
Healthcare
Industry
Biotechnology

Data sources: exchange quotes delayed 15 minutes, FINRA short interest, SEC filings, OPRA options data and third-party analyst data. Education only. Nothing on this page is a recommendation to buy or sell a security.